Lilly licenses diabetes programs to Transition; Millipore plans post-buyout growth;

 @FierceBiotech: The world's most expensive drugs. Report | Follow @FierceBiotech

 @JohnCFierce: Who needs poker when you can gamble on biotech stocks? Follow @JohnCFierce

> Transition Therapeutics will pay $1 million to in-license a set of preclinical compounds for diabetes from Eli Lilly, which is hanging on to an option to buy them back for up to $250 million if they prove to be hidden treasures. Even without the buyback, though, Lilly will earn low single-digit royalties on any of these programs that make their way to the market. Release | Report

> The CEO of Millipore tells the Boston Globe that the big buyout deal with Merck KGaA will pave the way to new growth for the company. Report

> With an FDA advisory meeting looming on InterMune's idiopathic pulmonary fibrosis drug pirfenidone, the developer has submitted the treatment for European approval. InterMune release | Report

> Merck is touting promising late-stage data for its allergy therapy--Phleum Pratense. Patients taking the treatment responded significantly better than those receiving a placebo. Story

> Stem Cell Innovations has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. Agennix release

> Nabi shareholders voted to approve the exclusive option and license agreement for NicVAX with GlaxoSmithKline Biologicals. Nabi release

And Finally... UC Irvine neurobiologists are providing the first visual evidence that learning promotes brain health--and, therefore, that mental stimulation could limit the debilitating effects of aging on memory and the mind. Article